Form D · Pharmaceuticals

UroGen Pharma Ltd.

Princeton, NJ · CIK 0001668243

Offering snapshot reported Aug 14, 2023 · SEC filing

Reported sold: $120M
Investors reported: 8
Minimum accepted: $0
First sale: Jul 26, 2023

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Aug 14, 2023	Initial	$120,000,000	No comparison	8	SEC filing

Offering details

Securities: Equity, Option to acquire, Security to be acquired, Other
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $3.24M
Finders' fees: $0
Form D file number: 021-489628

Equity offering includes Ordinary Shares and Pre-Funded Warrants to purchase Ordinary Shares and Ordinary Shares issuable upon the exercise of Pre-Funded Warrants.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
BofA Securities, Inc.	283942
H.C. Wainwright & Co., LLC	375

Source: Form D, filed Aug 14, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Elizabeth Barrett	Director, Executive
Arie Belldegrun, M.D.	Director
Cynthia Butitta	Director
Fred Cohen, M.D.	Director
Stuart Holden, M.D.	Director
Don Kim	Executive
Ran Nussbaum	Director
James A. Robinson, Jr.	Director
Mark Schoenberg, M.D.	Executive
Jason Smith	Executive
Leana Wen, M.D., M Sc	Director
Dan Wildman	Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

400 Alexander Park Drive 4th Floor
Princeton, NJ, 08540